Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.62 |
| ▸ | BRAF | P15056 | 6/20 | 0.50 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854954 | 0.89 | MAPK14 (0.60) | MAPK14BRAFMETMAPK13KDR | |
| SCHEMBL1136971 | 0.88 | MAPK14 (0.65) | MAPK14BRAFMETMAPK13KDR | |
| SCHEMBL2860620 | 0.86 | RAF1 (0.50) | MAPK14BRAFMAPK13KDRRIPK2 | |
| SCHEMBL3561767 | 0.85 | MAPK14 (0.61) | MAPK14BRAFMETMAPK13KDR | |
| SCHEMBL2858354 | 0.81 | MAPK14 (0.63) | MAPK14BRAFMETMAPK13KDR | |
| SCHEMBL12812041 | 0.81 | MAPK14 (0.51) | MAPK14BRAFMETKDRRAF1 | |
| SCHEMBL4321614 | 0.77 | MET (0.72) | MAPK14BRAFMETRAF1 | |
| SCHEMBL23201734 | 0.77 | MAPK14 (1.00) | MAPK14BRAFMAPK13KDRRIPK2 | |
| SCHEMBL29844389 | 0.77 | MAPK14 (1.00) | MAPK14BRAFMAPK13KDRRIPK2 | |
| SCHEMBL13635346 | 0.77 | MAPK14 (0.52) | MAPK14BRAFMETKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2248810-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-11-10 | — | — | EP | disclosed |
| EP-2248810-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009104520-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | TET2, QDPR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPK14 1986/4885BRAF 1722/4885MET 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.